Pay in 4 interest-free payments of $5.54 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
Clin Exp Allergy (2017) 47(3):3318
Through NRF2-driven GSH synthesis, tumor cells are protected from oxidative stress, which contributes to chemotherapy resistance by reducing the cytotoxic effects of ROS generated during treatment
384,385 The CAPItello-291 phase 3 study indicates that regardless of AKT pathway abnormalities, the capivasertib plus fulvestrant group demonstrates a significant advantage in median PFS compared to the placebo plus fulvestrant group
However, this study is available only as an abstract, and its reliability is largely unknown
US$ 23.72
US$ 21.94
US$ 23.10
